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Summary The expression of the EGF receptor, c-erbB-2 and PDGF receptor proteins has been studied in a
series of human brain tumour biopsies and cell lines. Western blotting was used to determine the amount of
protein present and their intrinsic and ligand promoted enzyme activities were studied by immunoprecipitation
followed by autophosphorylation. EGF receptors were found to be expressed at very high levels in 40% of
primary tumour biopsies, but at uniformly low levels in tumour derived cell lines. The c-erbB-2 protein was
not detected in tumour biopsies, but was present at variable, but low levels in extracts of tumour cell lines.
PDGF receptors were also found at moderate to low levels in both primary tumours and cell lines. The EGF
receptor gene was amplified in four out of 14 primary tumours and this generally correlated with high levels of
protein expression. The c-erbB-2 gene was not amplified. Employing the polymerase chain reaction and
sequence specific oligonucleotides as probes there was no evidence of mutations in the c-erbB-2 gene
transmembrane region. These results suggest that alterations of expression of the EGF receptor may play a
role in human brain tumours. There was however no evidence for aberrant expression of the c-erbB-2 protein.
Additional experiments are required to assess the influence of PDGF receptor expression in brain tumour cells.
Several clhanges occurring at the level of DNA are thought to
be required for full malignant transformation. One family of
molecules known to be capable ofinfluencing this process are
the growth factor receptors. Much evidence has emerged for
changes in the gene copy number, gene structure and level of
expression of a subset of these in certain types of human
cancers. The type one growth factor receptors, epidermal
growth factor receptor and the c-erbB-2 protein are often
overexpressed, predominantly in squamous cell carcinomas
(Ozanne et al., 1986) and adenocarcinomas (Gullick &
Venter, 1989) respectively.
Overexpression is often a consequence of gene amplific-
ation. Since this change very rarely happens in normal DNA
(Wright et al., 1990) it provides a strong indication of the
aberrant nature of this event. In some cases however, elevat-
ed receptor expression occurs as a consequence of increased
transcription which is less easy to characterise as abnormal
(Kraus et al., 1987; Slamon et al., 1989). Nonetheless, this
may have a significant influence on the disease process.
Several reports have indicated that the EGF receptor is
overexpressed at very high levels in some brain tumours as a
consequence of gene amplification (Libermann et al., 1985;
Wong et al., 1987). Some evidence suggests that mRNA for
the PDGF receptor and the PDGF A and B type growth
factors are expressed at moderate to high levels in brain
tumour biopsies (Hermansson et al., 1988; Nister et al., 1988)
and cell lines (Harsh et al., 1989). The c-erbB-2 protein is
expressed in certain areas of normal human foetal brain
(Quirke et al., 1989) but its possible role in human brain
tumours has not been studied. We have examined the gene
copy number, gene structure and level of protein expression
of the EGF receptor, c-erbB-2 and PDGF receptor in a
group of primary brain tumour biopsies and a series of brain
tumour derived cell lines. In addition we have looked for
potential activating mutations in the transmembrane
sequence of the c-erbB-2 gene (Segatto et al., 1988). Any
changes in these systems may be useful for more accurately
categorising tumours and provide targets for immunotherapy
or inhibitors of receptor function.
Materials and methods
Collection, storage and characterisation ofbrain tumours and
cell lines
Human gliomas were removed at surgery and the majority of
the sample was immediately snap-frozen in liquid nitrogen
and stored until analysis. Approximately 0.1 g of fresh biopsy
material was placed in a sterile tube containing Dulbecco's
minimum essential medium (DMEM), and an explant culture
set up from each sample as follows: The tumour sample was
finely minced with a scalpel and trypsinised to further dis-
sociate the cells. The cells were then cultured in DMEM
containing 10% foetal calf serum and subsequently repas-
saged as necessary. A proportion of the cultured cells were
frozen and stored in liquid nitrogen at every 2nd passage.
Cells lines were characterised at passage I or 2 to confirm
that they contained cells expressing glial markers. Expression
of glial cell markers, glial fibrillary ascidic protein (GFAP)
and galactocerebroside-C (gal-C) was assessed in early cul-
tures by standard immunocytochemical techniques (Franks &
Burrow, 1986). Cell lines were employed for analysing recep-
tor expression after between eight and 20 passages, depend-
ing on the particular cell line. Although none of these cell
lines were cloned, they were established and the vast majority
of the tumour cells in each culture exhibited a similar mor-
phology at the time of lysis.
The diagnosis on the solid tumours were made by consul-
tant neuropathologists at the National Hospitals for Nervous
Diseases, Maida Vale and Queen Square, London. The class-
ification was that described in Russel and Rubinstein (1977).
Preparation ofprimary brain tumour and brain tumour cell line
lysates
Lysate from the cell lines were prepared and their protein
concentration determined as described previously (Corbett et
al., 1990). Cell lysate was mixed with SDS PAGE sample
buffer containing reducing agent and boiled for 3 min and
stored at - 20°C until use in Western blots. A 5 mm cube
(approximately) of primary brain tumour was homogenised
in a glass homogeniser with I ml of ice cold lysis buffer, the
protein concentration was estimated using the method of
Bradford (1976). A portion of this was mixed with sample
buffer, boiled and stored at -20C until use in Western
blots. The remainder of the lysate was used immediately in
immunoprecipitation/phosphorylation experiments.
Correspondence: W.J. Gullick.
'Present address: Department of Pathology, University of Melborne,
Parkville 3052, Victoria, Australia.
Received 6 July 1990; and in revised form 24 September 1990.
'." Macmillan Press Ltd., 1991 Br. J. Cancer (1991), 63, 227-233228 N. L. TUZI et al.
Production ofantibodies to the murine and human PDGF
receptors
Antibodies to the murine and human PDGF receptor were
raised employing a synthetic peptide. The peptide sequence
GCPGPLAEAEDSFL, called 22P, (residues 1054-1067 at
the c-terminus of the murine PDGF receptor, Yarden et al.,
1986) were synthesised using the F-moc technique. Polyclonal
antibodies were raised in rabbits to the peptide, coupled
using glutaraldehyde, to keyhold limpet haemocyanin. Serum
titres were tested by ELISA against the immunising peptide
(22P) and against the cognate sequence in the human B type
PDGF receptor (residues 1093-1106, GCPAPRAEAEDSFL,
Gronwald et al., 1988) and A type receptor (residues
1076-1089, IGIDSSDLVEDSFL, Matsui et al., 1989). The
antibodies were evaluted by their ability to immunoprecip-
itate the PDGF receptor from the NR6 cell line (Bowen-Pope
et al., 1985). Cells were labelled with 35S-methionine and
immunoprecipitated as described previously (Waterfield et
al., 1982). In another experiment unlabelled cell lysate was
prepared and immunoprecipitated with or without an excess
of the immunising peptide 22P. The immune complexes were
incubated for 30 min at room temperature with or without
10- M porcine PDGF (a gift from Dr P. Stroobant) and
then 32P-gamma-ATP (final concentration 10tiM containing
3 iCi per immune complex) was added for 10min on ice.
The samples were then mixed with SDS PAGE sample buffer
containing reducing agent and subjected to electrophoresis on
7.5% gels.
Immunoprecipitation/phosphorylation of tumour tysates
Eight hundred fig of total cell lysate protein, prepared from
primary human brain tumour specimens, was immunoprecip-
itated with antibodies EGFR1 (Waterfield et al., 1982), 21N
(Gullick et al., 1987) or 22P to the EGF receptor, c-erbB-2
protein and PDGF receptor respectively. Control cell lines
used were A431 (Waterfield et al., 1982) for EGF receptor,
SKBR3 for c-erbB-2 (Gullick et al., 1989) and AG1523
(Claesson-Welsh et al., 1987) for PDGF receptor. PDGF
receptor was immunoprecipitated with 5 ,sl of antiserum from
rabbits immunised with synthetic peptide 22P, EGF receptor
with 2 fig of EGFR1 monoclonal antibody and c-erbB-2 with
5 ytg of affinity purified 21N antibody preloaded on 20 1tl of a
1:1 slurry of protein A sepharose, plus or minus 10 g of
competing 22P peptide for PDGF receptor or competing
peptide 21N for c-erbB-2. The Protein A Sepharose/antibody
complex was washed with 1 ml for PBS before the addition
of the cell lysate. Samples were tumbled at 4°C for 2 h and
then washed as described previously (Gullick et al., 1985)
with a final I ml wash of phosphorylation buffer. Stimulation
of kinase activity was attempted by the addition of 40 ng of
PDGF (PDGF c-sis, Amersham, UK) to give a final concen-
tration of 1 ng ll- for PDGF receptor and EGF purified
from mouse submaxillary glands to a final concentration of
10' M for the EGF receptor. Samples were incubated at
room temperature with the respective ligand for 40 min for
PDGF receptor and 30 min for EGF receptor prior to the
addition of 5lsCi of carrier free 32P-gamma ATP and a
further incubation for 20 min at room temperature. The re-
action was terminated by the addition of 20fil of 5 x SDS
PAGE sample buffer and boiling for 3 min.
Samples were run on a 5% polyacrylamide gel, stained
with Coomassie blue, destained, dried and autoradiographed
using Kodak XAR-5 film overnight at - 80°C.
Western blotting
One hundred 1tg of total cell protein from primary brain
tumours or 19 Lg from brain tumour cell lines were run on
5% polyacrylamide gels and transferred and detected as
previously described (Gullick et al., 1989).
Southern blotting
DNA was extracted from the tumours, digested with EcoRI
endonuclease, separated on a 0.8% agarose gel and transfer-
red to Hybond-N (Amersham, UK) membranes. The blots
were probed with purified insert of clone p64.1 from the
EGF receptor (Gullick et al., 1986b) and a 1.4Kb EcoRI
fragment of the c-erbB-2 cDNA (Venter et al., 1987). The
blots were reprobed with genomic human alpha-2-1 and
alpha-i-i collagen probes (situated on chromosomes 7 and
17 respectively), to estimate the amounts of DNA loaded
(Gullick et al., 1989). The blots were autoradiographed using
Kodak XAR-5 film and the extent of amplification estimated
by soft laser scanning densitometry.
PCR analysis ofc-erbB-2 transmembrane region in tumour
DNA
DNA was prepared from primary brain tumours and then
specifically amplified by the polymerase chain reaction as
previously described (Lemoine et al., 1990a) using the oligo-
nucleotides detailed in Hall et al. (1990).
Results
EGFreceptor
We examined the EGF receptor protein and its gene in a
series of primary human tumour biopsies and in several brain
tumour-derived cell lines (Table I). In extracts of 14 primary
tumours very variable levels of receptor protein expression
was observed in the different samples by Western blotting
employing either an antipeptide antibody to the receptor's
ATP binding site (ISE, Gullick et al., 1986a, data not shown)
or an antibody to a region between the kinase domain and
the autophosphorylation site domain (2E, Gullick et al.,
1986b) (Figure 1). Both antibodies however, gave consistant
results. Immunoprecipitation and phosphorylation of
immune complexes from tumour lysates showed concordant
large variations in receptor expression (Figure 2) suggesting
that the receptor was enzymatically active in these specimens.
In each case preincubation of the immune complexes with a
saturating concentration of EGF stimulated autophosphory-
lation (Figure 2) indicating that the receptor isolated from
tumours 8 and 14 were activated by ligand binding. Lower
exposure of the gel demonstrated that tumour 13 was also
stimulated (data not shown).
It has been reported previously (Libermann et al., 1985;
Wong et al., 1987) that the EGF receptor gene is commonly
amplified in high grade gliomas. We therefore examined the
EGF receptor gene structure and copy number by Southern
blotting. Four of the 14 (29%) tumours examined displayed
additional copies of the EGF receptor gene when compared
to the single copy alpha-2-t and alpha-i-i collagen genes
situated on chromosomes 7 and 17 respectively (Figure 3).
There was no evidence of selective reduplication of chromo-
some 7 in any of these tumours, as determined by densito-
metric scanning of the autoradiographic signal produced by
the alpha-2-1 and alpha-i-i collagen gene probes. With the
one restriction enzyme employed there was no sign of gene
rearrangement. In several cases there was a relationship
between high levels of protein expression observed by
Western blotting and/or kinase activity with amplification
of the EGF receptor gene (Table II). Tumour 8 and 13
however, appear to express high levels of receptor protein
without evident gene amplification and tumour 9 gene ampli-
fication without grossly elevated levels of receptor protein.
This discrepancy may be due to the necessity to use different
fragments of the tumour in each assay system and the diffi-
culty in reliably confirming the presence of tumour cells in
each region of the biopsy.
Some reports have suggested that the EGF receptor is
rarely overexpressed or its gene amplified in cell lines derived
from brain tumours (Humphrey et al., 1988). We therefore
examined the expression of the EGF receptor in a series of
11 independently derived cell lines. Each line gave a surpris-
ingly similar signal (data not shown) suggesting a low level of
expression relative to A431 cell lysate used as a positiveGROWTH FACTOR RECEPTORS IN BRAIN TUMOURS 229
Table I Pathological diagnosis of brain tumours and cell lines
Tumour Cell
code Diagnosis line Diagnosis
1 Glioblastoma multiforme (GMB) 17/81 Astrocytoma Grade I
2 GBM IN/259 Astrocytoma Grade IV
3 Malignant glioma IN/293 GBM
4 Mixed Oligo-astrocytoma Grade III IN/353 Malignant Glioma Grade IV
5 GBM IN/392 Medulloblastoma
6 GBM IN/859 GBM
7 GBM IN/938 Oligodendroglioma
8 GBM IN/981 Astrocytoma Grade II
9 GBM IN/1025 GBM
10 Malignant astrocytoma Grade III IN/1056 Astrocytoma Grade IV
11 GBM IN/I 113 Astrocytoma Grade I
12 GBM
13 GBM
14 Malignant glioma*..-.........
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Figure 1 Western blot of EGF receptors from extracts of
primary brain tumours. Track 1, molecular weight markers;
tracks 2-15, tumours 1-14; tracks 16-17, 1 and 3 g A431 cell
membranes.
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Figure 2 Immunoprecipitation and phosphorylation of EGF
receptors from primary brain tumours. Tracks 1-5, tumours 13,
8, 12, 14, A431 membranes; tracks 6-10, tumours 13, 8, 12, 14,
A431 membranes incubated with EGF. All immunoprecipitated
with antibody EGFR1 to the EGF receptor.
control. Subsequently, as shown below, additional aliquots of
the same cell lysates showed variable amounts of other
growth factor receptors indicating that this was not an
artifactual result.
c-erbB-2
In initial experiments no c-erbB-2 protein expression was
observed either by Western blotting or by immunoprecipita-
tion followed by phosphorylation of the same primary
tumour cell lysates. We therefore attempted to optimise the
conditions of the phosphorylation reaction to increase the
sensitivity of the assay. Since no ligand for the c-erbB-2
protein was available to stimulate phosphorylation, we exam-
ined the metal ion, time and temperature dependence of the
reaction employing a chimeric protein consisting of the extra-
cellular domain of the EGF receptor and the intracellular
kinase domain to rat neu protein expressed at high levels in
NIH3T3 cells (Lehvaslaiho et al., 1989). Autophosphoryla-
tion of the construct in response to EGF was employed as an
indication of receptor activation. It was found that 3 mM
MnCl2 gave maximal autophosphorylation but that MgCl2
did not support the reaction. Combinations of the two ions
did not enhance autophosphorylation further. It was also
found that maximal autophosphorylation was observed at
room temperature and 15 min of incubation (data not
shown). Despite several subsequent attempts employing these
conditions no c-erbB-2 protein expression was detected in the
tumour extracts. When the Southern blot shown in Figure 3
was reprobed to detect the c-erbB-2 gene no differences in
fragment pattern or intensities were observed relative to nor-
mal DNA (data not shown), indicating no detectable gene
rearrangement or amplification.
It was still possible, however, that the c-erbB-2 protein
might be expressed at low levels in the tumours. Activating
mutations in the transmembrane region of the rat neu gene
have been observed which lead to cell transformation despite
low levels of protein expression (Bargmann & Weinberg,
1988). Similar mutations artifically introduced into human
c-erbB-2 have the same effect (Segatto et al., 1988). We
therefore examined the sequence of the c-erbB-2 transmem-
brane region in DNA extracted from these tumours for the
presence of such mutations. DNA was amplified by PCR and
probed with wild type and mismatched oligonucleotides as
described by Lemoine et al. (1990a). No mutations were
found in this region of the gene (data not shown).
We next examined the tumour cell lines for c-erbB-2 ex-
pression by Westem blotting. The c-erbB-2 protein was
detected at variable but generally low levels in all of the cell
lines tested. In one case, cell line lN/392 (Figure 4, track 8),
a somewhat higher level of c-erbB-2 protein was observed.
Much less protein was seen however than present in extracts
of the overexpressing breast cancer cell line SKBR-3 (Figure
4).
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PDGF receptor
Polyclonal antipeptide antibodies were raised in rabbits to
the c-terminal 13 amino acids of the mouse B-type PDGF
receptor. In ELISA reactions these were shown to react with
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Figure 3 Southern blot of DNA from brain tumours probed for
the EGF receptor. a, examples of EGF receptor gene
amplification: track N: placental DNA; tracks 1-10, brain
tumours; tracks 2 (tumour 10) and 9 (tumour 14) show ampli-
fication of 12 and 9 fold respectively of the EGF receptor gene.
Track 1, tumour 11; track 3, tumour 7; track 4, tumour 6; track
5, tumour 8; track 6, tumour 12; track 7, tumour 13; track 8,
tumour 12; track 10, tumour 1. b, Reprobed with alpha-2-1
collagen gene on chromosome 7 to normalise for loading of
DNA.
the immunising peptide and to cross react strongly and to an
equal extent with the cognate sequence from the human
B-type receptor and the less related sequence in the human
A-type receptor (data not shown). Immunoprecipitation of
"S-methionine labelled cell lysate from the mouse cell line
NR6 (known to express high levels of PDGF receptors,
Bowen-Pope et al., 1985) revealed the presence of two specific
bands, one minor, sharp band running a 160 Kd and a major
diffuse band at 185 Kd (Figure 5a). These are identical in size
and appearance to the partially glycosylated and fully glyco-
sylated PDGF receptor respectively (see for instance Hart et
al., 1987). In order to confirm the identity of these species
cell lysates were immunoprecipitated and treated with or
without PDGF and then autophorphosylated with 32P-
gamma-ATP. Both bands were again seen and their level of
phosphorylation was increased following preincubation with
PDGF (Figure Sb). In all cases preincubation of the anti-
bodies with the immunising peptide prevented immunopre-
cipitation.
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Figure 4 Western blot for c-erbB-2 in various brain tumour
derived cells lines. Track 1, molecular weight markers; tracks
2-16, cell lines 17/18, IN/259, IN/293, IN/293, U-251, lN/353,
IN/392, U-251, U-251, IN/859, IN/938, IN/981, IN/1025, IN/
1056, lN/1113; tracks 17 and 18, 5 and l0jig of SKBR-3 cell
lysate.
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Figure 5 a, Immunoprecipitation of PDGF receptor from NR6
mouse fibroblasts labelled with 35S methionine. Track 1, 5Al
antibodies to the PDGF receptor; track 2, 5 lAl antibodies to the
PDGF receptor preincubated with immunizing peptide. b,
Immunoprecipitation and phosphorylation of PDGF receptors
from NR6 cells. Tracks I and 3, antibody to PDGF receptor;
tracks 2 and 4, preincubated with peptide; tracks 3 and 4 plus
PDGF; tracks 1 and 2, minus PDGF.
Table II Summary of receptor protein expression, kinase activity and gene copy number
EGF-Receptor PDGF-R
Western Southern Immpt/ Immpt/ Cell EGFR c-erbB-2 PDGFR
Tumour blot blot Phos. Phos. line Western Western Western
1 + - N/A + 17/81 + + + +
2 + + - N/A + + IN/259 + + +
3 - - N/A IN/293 + + + +
4 - N/A + IN/353 + + + +
5 + + + 13 x N/A IN/392 + + ++ -
6 + - N/A IN/859 + + + +
7 + - N/A + lN/938 + + + +
8 + + - + + + + + IN/981 + + + +
9 5 x N/A - IN/1025 + + + +
10 + + 12 x N/A/ + + IN/1056 + +
11 + - N/A/ +++ IN/1113 + ++ ++
12 + - - ++
13 ++ - +++ +++
14 ++ 9x + +GROWTH FACTOR RECEPTORS IN BRAIN TUMOURS 231
Brain tumour lysates were immunoprecipitated with anti-
bodies to the PDGF receptor and the immune complexes
phosphorylated. Autoradiography revealed that several
tumours contained detectable levels of receptors (Figure 6,
Table II) which were similar in size to the receptor recognised
in the human cell line AG1523 (Figure 6, tracks 16-18).
Several other strongly labelled bands were also observed.
However, these were present even following preincubation of
the antibody with the immunising peptide. It seems likely
that these are present non-specifically in the immunoprecip-
itates and became labelled upon the addition of ATP. We
have not investigated their identity further. Western blotting
of the same tumours did not, however, detect PDGF receptor
expression suggesting that the phosphorylation technique is
much more sensitive. Western blotting of tumour cell lines
did show expression of PDGF receptors at variable but
barely detectable levels (data not shown) supporting this
premise.
Discussion
The EGF receptor is expressed at low levels in the normal
human brain. Some conflict exists however as to its relative
expression on neurons, glial cells and astrocytes. Immunohis-
tochemical staining demonstrated receptors on many types of
nerve cells but not on astrocytes and glial cells (Werner et al.,
1988). Direct binding of iodinated EGF to primary cultures
of rat brain cells, however, demonstrated higher levels of
receptors on glial cells than on neurons (Wang et al., 1989).
Several reports have indicated that vastly increased numbers
of receptors are frequently found on certain human brain
tumour cells. In this work we confirm that the EGF receptor
gene is commonly amplified in glioblastomas of high grade
leading to greatly elevated levels of receptor expression. The
incidence of 29% of amplification in this small study is
consistent with that reported previously (Libermann et al.,
1985; Wong et al., 1987). With the one restriction enzyme
employed we saw no evidence of gene rearrangement in these
specimens. Other have reported rearrangements to occur
quite frequently in amplified cases (Humphrey et al., 1988
(5/6); Libermann et al., 1985 (2/4); Wong et al., 1987 (6/14);
Yamazaki et al., 1988 (2/2)). Further studies with a panel of
restriction endonucleases would be required to more fully
exclude the possiblity of rearrangements in our cases. Ampli-
fication led to high levels of EGF receptor protein expression
which was capable of autophosphorylation indicating that it
was enzymatically active. Yamazaki et al. (1988) have found
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Figure 6 Immunoprecipitation and phosphorylation of PDGF
receptors from primary brain tumours. Tracks 1-3, tumour 7; tracks 4-6, tumour 8; tracks 7-9, tumour 9; tracks 10-12,
tumour 10; tracks 13-15, human foreskin fibroblasts; tracks
16-18, AG1523 cells. Those tracks indicated +PEP represent immunoprecipitates in which immunising peptide has been added
as a competitive inhibitor of immunoprecipitation.
that in two cases of glioblastoma multiforme where there was
an amplified, rearranged EGF receptor gene, the protein
product was consitutively active in that addition of EGF to
an immune complex kinase assay did not promote additional
autophosphorylation. In our immunoprecipitation kinase
assays however, in each case addition of EGF did promote
receptor autophosphorylation demonstrating that the recep-
tors were not fully activated. Conversely, a report has
appeared in which the EGF receptor gene was found to be
amplified in the human glioblastoma cell line SF268, but the
protein expressed was enzymatically inactive (Wells et al.,
1988). In another publication this line bound EGF which
could be crosslinked to a protein of the same size as the EGF
receptor, but the cells were unresponsive to EGF (Westphal
et al., 1985). In this study we found uniformly low levels of
expression of EGF receptor protein in all the cell lines
studied. It is possible that overexpression of EGF receptors
in brain tumours is a selective advantage in vivo, but a
disadvantage to cells in culture (Humphrey et al., 1988) and
that mutation may have occurred in the EGF receptor gene
in the SF268 cell line which inactivates the receptors catalytic
activity (Wells et al., 1988).
Overexpression of EGF receptors in breast cancer is asso-
ciated with poor prognosis (Sainsbury et al., 1987). It is not
known whether overexpression in brain tumours defines a
subgroup of tumours with different biological characteristics.
Study of this is currently hampered by the lack of immuno-
logical reagents which reliably detect EGF receptor expres-
sion in paraffin embedded archival material. The high levels
of receptor expression do however provide a target for
immunoscintigraphy (Takahashi et al., 1987) and immuno-
therapy (Epenetos et al., 1985; Kalofonos et al., 1989) and
novel forms of receptor inhibitors (Gullick, 1990).
We found no evidence of aberrant expression or gene
amplification of c-erbB-2 in any of the primary tumour biop-
sies. Amplification and overexpression of this gene occurs in
about 20% of breast (Slamon et al., 1989; Gullick et al.,
1990), stomach (Falck & Gullick, 1989) and ovarian cancers
(Slamon et al., 1989) and with a lower frequency in other
tumour types (Hall et al., 1990; Yokota et al., 1986; Lemoine
et al., 1990b). The c-erbB-2 protein, detected by Western
blotting, was expressed at low, variable levels in the cell lines,
but not in the primary tumour biopsies. It may be that it is
also expressed in the primary tumours, but at levels below
our limit of detection. c-erbB-2 protein is normally expressed
in some areas of foetal (Quirke et al., 1989) and adult
(Quirke & Gullick, unpublished results) human brain.
We can conclude that amplification and overexpression of
the c-erbB-2 protein is probably a rare event in human brain
tumours, if it occurs at all. However, it was possible that low
level expression of a mutant c-erbB-2 protein could occur
and we therefore examined the gene for mutations at position
659 in the amino acid sequence. Previously this has been
shown to occur in a rat carcinogenesis model leading to
tumours of the CNS (Bargmann & Weinberg, 1988) and an
equivalent change can convert the human gene-To a powerful
oncogene (Segatto et al., 1988). Using PCR and mismatched
oligonucleotide hybridisation we saw no evidence of muta-
tions in this region of the gene. Previously we have also
found no mutations in a large series of breast (Lemoine et
al., 1990a), pancreatic (Hall et al., 1990) and thyroid tumours
(Lemoine et al., 1990b). It is apparent that this change may
be confined to the rat chemical carcinogenesis model.
The tumours were also examined for the expression of the
PDGF receptor protein. The detailed distribution of PDGF
receptors in the human brain is not known. Receptors are,
however, expressed on normal cultured human glial cells
(Heldin et al., 1981), astrocytes (Richardson et al., 1988) and
rat neurons (Smits et al., 1990). Receptors are also present on
transformed cell lines derived from gliomas (Nister et al.,
1986; Nister et al., 1988). In addition, several studies have
demonstrated the production of PDGF A chain and PDGF
B chain by cultured glial cells (Betsholtz et al., 1986) and
neuroblastoma cells (van Zoelen et al., 1985) and in primary
brain tumours (Hermanssen et al., 1988). A characteristic of232 N. L. TUZI et al.
high grade gliomas is the large amount of reactive endothelial
cells present. Human umbilical vein endothelial cells do not
appear to possess PDGF receptors, but they do secrete
PDGF (Dicorleto & Bowen-Pope, 1983; Barrett et al., 1984;
Collins et al., 1985) although this may be slightly different in
structure to that made by glial cells (Tong et al., 1987).
Interestingly however, in situ hybridisation of three cases of
glioblastoma multiforme revealed quite high levels of appar-
ent PDGF receptor mRNA in proliferating tumour asso-
ciated endothelial cells suggesting a possible autocrine or
paracrine growth mechanism (Hermansson et al., 1988). In
this study we show that the PDGF receptor protein was
present in several primary tumour extracts and was cata-
lytically active. It was also present at low, variable levels in
many of the cell lines examined indicating that the receptor
was present in tumour cells. No reports have ever indicated
that the PDGF receptor gene is amplified in any human
tumours.
The critical question is whether either the production of
PDGF or its receptors is abnormal in the tumours and is
promoting their transformed phenotype. Detailed studies of
the relative levels of receptor and ligand expression by nor-
mal and transformed cells are required to address this point.
It seems however that there is circumstantial evidence for
their involvement.
In summary, the EGF receptor gene is amplified and
overexpressed in human brain tumours. From this work,
however, it appears that although the c-erbB-2 protein is
expressed in brain tumour cell lines, there is no evidence that
this expression is abnormal. PDGF receptor expression could
be demonstrated in human brain tumours and it may be that
the PDGF system is influential in tumour cell growth regula-
tion, but more experiments are required to address this issue.
We are grateful to Miss Zoe Redley for preparing this manuscript.
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